Treatment of patients with HCV related cirrhosis: many rewards with very few risks

Area of Science:

• Hepatology
• Virology
• Internal Medicine

Background:

• Chronic hepatitis C virus (HCV) treatment aims for sustained virological response (SVR) to prevent liver complications and improve survival.
• Patients with HCV-related compensated cirrhosis benefit most from viral clearance, with SVR positively impacting liver complication rates.
• The mechanisms behind SVR benefits (viral clearance vs. histological improvement) and interferon (IFN)-based therapy efficacy in cirrhosis remain debated.

Purpose of the Study:

• To evaluate the efficacy of antiviral treatments in patients with HCV-related compensated cirrhosis.
• To explore alternative treatment strategies for HCV in patients with cirrhosis, given the limitations of IFN-based regimens.
• To identify the need for novel antiviral regimens that do not rely on IFN for viral clearance.

Main Methods:

• Review of retrospective studies on SVR and liver complications in HCV patients.
• Analysis of treatment outcomes for interferon (IFN)-based therapies, including low-dose pegylated IFN (PegIFn) monotherapy.
• Assessment of the impact of viral clearance and histological improvements on patient outcomes.

Main Results:

• SVR is associated with positive modification of liver complication rates in HCV patients with compensated cirrhosis.
• Cirrhosis is a significant factor associated with reduced efficacy of IFN-based regimens.
• Alternative strategies like low-dose PegIFn monotherapy have demonstrated limited efficacy.

Conclusions:

• Viral clearance through SVR is critical for managing HCV-related compensated cirrhosis.
• Current IFN-based treatments face challenges in patients with cirrhosis, necessitating alternative approaches.
• Development of novel antiviral regimens independent of IFN's broad effect is highly anticipated for effective HCV treatment.